Exforge copycats to hit markets

The patent for Novartis’s Exforge, a drug with two most important ingredients for the treatment of hypertension, is set to expire early April in Korea so a swarm of generic versions can hit the market.

The release of generics is expected to give wider and easier access to treatment for people suffering from hypertension, since prices are expected to be far lower than for the original drug.
...